Self-administration of injectable contraception: a systematic review and meta-analysis - PubMed (original) (raw)
Self-administration of injectable contraception: a systematic review and meta-analysis
Caitlin E Kennedy et al. BMJ Glob Health. 2019.
Abstract
Introduction: Depot medroxyprogesterone acetate subcutaneous injectable contraception (DMPA-SC) may facilitate self-administration and expand contraceptive access. To inform WHO guidelines on self-care interventions, we conducted a systematic review and meta-analysis comparing self-administration versus provider administration of injectable contraception on outcomes of pregnancy, side effects/adverse events, contraceptive uptake, contraceptive continuation, self-efficacy/empowerment and social harms.
Methods: We searched PubMed, Cumulative Index to Nursing and Allied Health Literature, LILACS and EMBASE in September 2018 for peer-reviewed studies comparing women who received injectable contraception with the option of self-administration with women who received provider-administered injectable contraception on at least one outcome of interest. Risk of bias was assessed using the Cochrane tool for randomised controlled trials (RCTs) and the Evidence Project tool for non-randomised studies. Meta-analysis was conducted using random-effects models to generate pooled estimates of relative risk (RR).
Results: Six studies with 3851 total participants met the inclusion criteria: three RCTs and three controlled cohort studies. All studies examined self-injection of DMPA-SC; comparison groups were either provider-administered DMPA-SC or provider-administered intramuscular DMPA. All studies followed women through 12 months of contraceptive coverage and measured (dis)continuation of injectable contraception. Meta-analysis found higher rates of continuation with self-administration compared with provider administration in three RCTs (RR: 1.27, 95% CI 1.16 to 1.39) and three controlled cohort studies (RR: 1.18, 95% CI 1.10 to 1.26). Four studies reported pregnancies; all showed no difference across study arms. Four studies reported side effects/adverse events; while two controlled cohort studies showed increased injection site reactions with self-administration, no other side effects increased with self-administration. One study found no difference in social harms. No studies reported measuring uptake or self-efficacy/empowerment.
Conclusion: A growing evidence base suggests that self-administration of DMPA-SC can equal or improve contraceptive continuation rates compared with provider administration. This benefit comes without notable increases in pregnancy or safety concerns. Self-injection of DMPA-SC is a promising approach to increasing contraceptive use.
Keywords: DMPA; injectable contraceptive; meta-analysis; self-administration; systematic review.
Conflict of interest statement
Competing interests: None declared.
Figures
Figure 1
PRISMA flow chart showing disposition of citations through the search and screening process. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 2
Meta-analysis of contraceptive continuation: results from randomised controlled trials.
Figure 3
Meta-analysis of contraceptive continuation: results from observational studies.
Comment in
- Evidence-Based Guidance for Self-Administration of Injectable Contraception.
Marx M. Marx M. J Midwifery Womens Health. 2021 Jan;66(1):108-112. doi: 10.1111/jmwh.13190. Epub 2020 Dec 27. J Midwifery Womens Health. 2021. PMID: 33369137
Similar articles
- Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
Burke HM, Chen M, Buluzi M, Fuchs R, Wevill S, Venkatasubramanian L, Dal Santo L, Ngwira B. Burke HM, et al. Lancet Glob Health. 2018 May;6(5):e568-e578. doi: 10.1016/S2214-109X(18)30061-5. Epub 2018 Mar 8. Lancet Glob Health. 2018. PMID: 29526707 Clinical Trial. - Continuation of self-injected versus provider-administered contraception in Senegal: a nonrandomized, prospective cohort study.
Cover J, Ba M, Drake JK, NDiaye MD. Cover J, et al. Contraception. 2019 Feb;99(2):137-141. doi: 10.1016/j.contraception.2018.11.001. Epub 2018 Nov 12. Contraception. 2019. PMID: 30439358 Free PMC article. - Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda.
Cover J, Namagembe A, Tumusiime J, Nsangi D, Lim J, Nakiganda-Busiku D. Cover J, et al. Contraception. 2018 Nov;98(5):383-388. doi: 10.1016/j.contraception.2018.03.032. Epub 2018 Apr 11. Contraception. 2018. PMID: 29654751 Free PMC article. - Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review.
Aderoba AK, Steyn PS, Kiarie JN. Aderoba AK, et al. Syst Rev. 2023 Jul 4;12(1):114. doi: 10.1186/s13643-023-02216-2. Syst Rev. 2023. PMID: 37403147 Free PMC article. Review. - The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
Dragoman MV, Gaffield ME. Dragoman MV, et al. Contraception. 2016 Sep;94(3):202-15. doi: 10.1016/j.contraception.2016.02.003. Epub 2016 Feb 10. Contraception. 2016. PMID: 26874275 Review.
Cited by
- Adolescent and covert family planning users' experiences self-injecting contraception in Uganda and Malawi: implications for waste disposal of subcutaneous depot medroxyprogesterone acetate.
Burke HM, Packer C, Wando L, Wandiembe SP, Muwereza N, Pradhan S, Zingani A, Ngwira B. Burke HM, et al. Reprod Health. 2020 Aug 3;17(1):117. doi: 10.1186/s12978-020-00964-1. Reprod Health. 2020. PMID: 32746860 Free PMC article. - Missed opportunity for self-injectable contraception awareness and adoption: Insights from client exit interviews in Uganda and Nigeria.
Ontiri S, Rothschild C, Nakimuli D, Adeoye O. Ontiri S, et al. Contracept X. 2023 Aug 7;5:100098. doi: 10.1016/j.conx.2023.100098. eCollection 2023. Contracept X. 2023. PMID: 37706059 Free PMC article. - Reclassifying contraceptives as over-the-counter medicines to improve access.
Ammerdorffer A, Laws M, Narasimhan M, Lucido B, Kijo A, Say L, Awiligwe A, Chinery L, Gülmezoglu AM. Ammerdorffer A, et al. Bull World Health Organ. 2022 Aug 1;100(8):503-510. doi: 10.2471/BLT.21.287561. Epub 2022 Jun 22. Bull World Health Organ. 2022. PMID: 35923274 Free PMC article. Review. - Self-injected contraceptives: does the investment reflect women's preferences?
Wood SN, Magalona S, Zimmerman LA, OlaOlorun F, Omoluabi E, Akilimali P, Guiella G, Gichangi P, Anglewicz P. Wood SN, et al. BMJ Glob Health. 2022 Jul;7(7):e008862. doi: 10.1136/bmjgh-2022-008862. BMJ Glob Health. 2022. PMID: 35835480 Free PMC article. Review. - Self-care interventions for sexual and reproductive health in humanitarian and fragile settings: a scoping review.
Dawson A, Tappis H, Tran NT. Dawson A, et al. BMC Health Serv Res. 2022 Jun 7;22(1):757. doi: 10.1186/s12913-022-07916-4. BMC Health Serv Res. 2022. PMID: 35672763 Free PMC article. Review.
References
- Brady M. Women’s self-care: a new take on an old practice. Seattle, Washington: PATH, 2018.
- Murray M, Brady M, Drake JK. Women's self-care: products and practices. Seattle, Washington: PATH, 2017.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous